Targeting the Hippo Pathway in Breast Cancer: A Proteomic Analysis of Yes-Associated Protein Inhibition
International Journal of Molecular Sciences · 22.04.2025 · 26 (9) · 3943
DOI: 10.3390/ijms26093943 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 22.04.2025. Verfasst von Sevinc Yanar und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Histology and Embryology, Faculty of Medicine, Sakarya University, 54187 Sakarya, Turkey. Hauptthemen laut MEDLINE: Proteomics, Protein Serine-Threonine Kinases, Signal Transduction, Transcription Factors. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Scientific and Technological Research Council of Turkey.
Abstract (Originalsprache)
The dysregulation of the Hippo signaling pathway leads to the aberrant activation of oncogenic YAP and TAZ, driving tumor progression. In breast cancer, this disruption promotes proliferation and metastasis. This study investigates the effects of CA3, a selective YAP inhibitor, on the proteome of triple-negative breast cancer MDA-MB-231 and luminal-A-like MCF7 cells. Proteomic changes were analyzed via nano-LC-MS/MS, while cytotoxicity, apoptosis, and autophagy were assessed through WST-1 assays, flow cytometry, and Western blot analyses. Bioinformatics tools were employed to identify enriched pathways. MDA-MB-231 cells exhibited an increased expression of DNA repair proteins (p < 0.05), indicating a compensatory response to maintain genomic stability. In contrast, MCF7 cells showed a downregulation of DNA repair factors (p < 0.005). Additionally, metabolic reprogramming was apparent in MCF7 cells (p < 0.001). Apoptosis assays revealed a rise in cell death, while cell cycle analysis indicated pronounced G1-phase arrest in MDA-MB-231 cells (p < 0.01). Moreover, autophagic suppression was particularly evident in MCF7 cells. This study, for the first time, provides evidence that breast cancer subtypes exhibit distinct dependencies on YAP-driven pathways, revealing potential therapeutic vulnerabilities. Targeting Hippo signaling alongside DNA repair in triple-negative breast cancer or combining YAP inhibition with metabolic blockade in luminal breast cancer holds significant potential to enhance treatment efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Histology and Embryology, Faculty of Medicine, Sakarya University, 54187 Sakarya, Turkey.
- Department of Medical Biology, Faculty of Medicine, Kocaeli University, 41380 Kocaeli, Turkey.
- Department of Medical Biology, Faculty of Medicine, Sakarya University, 54187 Sakarya, Turkey.
- Department of Physiology, Faculty of Medicine, Sakarya University, 54187 Sakarya, Turkey.
ORCID-Profile: Sevinc Yanar, Merve Gulsen Bal Albayrak, Tuğcan Korak, Asuman Deveci Ozkan, Sevil Arabacı Tamer
Förderung
- Scientific and Technological Research Council of Turkey
Zitieren
APA
Yanar, S., Bal Albayrak, M. G., Korak, T., Deveci Ozkan, A., Arabacı Tamer, S., & Kasap, M. (2025). Targeting the Hippo Pathway in Breast Cancer: A Proteomic Analysis of Yes-Associated Protein Inhibition. International Journal of Molecular Sciences, 26(9), 3943. https://doi.org/10.3390/ijms26093943
Vancouver
Yanar S, Bal Albayrak MG, Korak T, Deveci Ozkan A, Arabacı Tamer S, Kasap M. Targeting the Hippo Pathway in Breast Cancer: A Proteomic Analysis of Yes-Associated Protein Inhibition. International Journal of Molecular Sciences. 2025;26(9):3943. doi:10.3390/ijms26093943
BibTeX
@article{Yanar2025,
author = {Yanar, Sevinc and Bal Albayrak, Merve Gulsen and Korak, Tuğcan and Deveci Ozkan, Asuman and Arabacı Tamer, Sevil and Kasap, Murat},
title = {Targeting the Hippo Pathway in Breast Cancer: A Proteomic Analysis of Yes-Associated Protein Inhibition},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {9},
pages = {3943},
doi = {10.3390/ijms26093943}
}
EUVIMED